Cover Image
市場調查報告書

Cubist Pharmaceuticals, Inc.的產品平台分析

Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 240917
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
Cubist Pharmaceuticals, Inc.的產品平台分析 Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2014
出版日期: 2014年05月21日 內容資訊: 英文 81 Pages
簡介

Cubist Pharmaceuticals, Inc.是從事因應急性疾病治療上未滿足需求之治療製品之研究、開發、商品化的生物醫藥品企業。

本報告提供Cubist Pharmaceuticals, Inc.的治療藥開發平台現狀與各開發階段的比較分析,藥物標的,作用機制,給藥途徑,各分子類型治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Cubist Pharmaceuticals, Inc.的基本資料

Cubist Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Cubist Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Cubist Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Cubist Pharmaceuticals, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Cubist Pharmaceuticals, Inc.:藥物簡介

  • (ceftolozane + tazobactam)
  • tedizolid phosphate
  • bevenopran
  • fidaxomicin
  • solithromycin
  • surotomycin
  • CB-618
  • CB-027
  • GP-4
  • 阻礙DHFR的細菌感染疾病用的小分子
  • 細菌感染疾病用的小分子
  • 沒被GPCR為目標的公開的醫藥品

Cubist Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Cubist Pharmaceuticals, Inc.:最近的開發平台趨勢

Cubist Pharmaceuticals, Inc.:暫停中的計劃

Cubist Pharmaceuticals, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • (libivirumab + exbivirumab)
    • ADL-100101
    • ADL-5747
    • ADL-5859
    • CB-182804
    • CB-183872
    • CB-625
    • ecallantide
    • loperamide hydrochloride
    • Marine Natural Products Program

Cubist Pharmaceuticals, Inc.:企業發表

Cubist Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04779CDB

Global Markets Direct's, 'Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Cubist Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cubist Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cubist Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cubist Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cubist Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Cubist Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cubist Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cubist Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cubist Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cubist Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cubist Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cubist Pharmaceuticals, Inc. Snapshot
    • Cubist Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Cubist Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Cubist Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Cubist Pharmaceuticals, Inc. - Pipeline Products Glance
    • Cubist Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Cubist Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Cubist Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Cubist Pharmaceuticals, Inc. - Drug Profiles
    • (ceftolozane + tazobactam)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tedizolid phosphate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevenopran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fidaxomicin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • solithromycin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • surotomycin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-618
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-027
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GP-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DHFR for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Undisclosed Drug Targeting GPCRs
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cubist Pharmaceuticals, Inc. - Pipeline Analysis
    • Cubist Pharmaceuticals, Inc. - Pipeline Products by Target
    • Cubist Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Cubist Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Cubist Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Cubist Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Cubist Pharmaceuticals, Inc. - Dormant Projects
  • Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • (libivirumab + exbivirumab)
      • ADL-100101
      • ADL-5747
      • ADL-5859
      • CB-182804
      • CB-183872
      • CB-625
      • ecallantide
      • loperamide hydrochloride
      • Marine Natural Products Program
  • Cubist Pharmaceuticals, Inc. - Company Statement
  • Cubist Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cubist Pharmaceuticals, Inc., Key Information
  • Cubist Pharmaceuticals, Inc., Key Facts
  • Cubist Pharmaceuticals, Inc. - Pipeline by Indication, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Cubist Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Cubist Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014
  • Cubist Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Cubist Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014
  • Cubist Pharmaceuticals, Inc. - Pre-Registration, 2014
  • Cubist Pharmaceuticals, Inc. - Phase III, 2014
  • Cubist Pharmaceuticals, Inc. - Phase II, 2014
  • Cubist Pharmaceuticals, Inc. - Phase I, 2014
  • Cubist Pharmaceuticals, Inc. - Preclinical, 2014
  • Cubist Pharmaceuticals, Inc. - Discovery, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline by Target, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Cubist Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014
  • Cubist Pharmaceuticals, Inc. - Dormant Developmental Projects,2014
  • Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014
  • Cubist Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Cubist Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014
  • Cubist Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014
  • Cubist Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014
  • Cubist Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Cubist Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top